Denmark's Ascendis Forms $80 Million China Rare Disease JV with Vivo Capital

Ascendis Pharma of Denmark formed a China JV with Vivo Capital to develop its endocrinology rare disease therapies in Greater China. An investor syndicate, led by Vivo Capital, will own a 50% stake in Visen Pharma, the JV, in return for a $40 million investment. Sofinnova also participated in the funding. Ascendis will transfer China rights to three of its rare disease drugs into Visen and own the remaining 50%. The three Ascendis products -- TransCon hGH, TransCon PTH and TransCon CNP -- are in late-stage clinical trials outside of China . Stock Symbols: (NSDQ: ASND) Share this with colleagues: // //